一种靶向HER2阳性乳腺癌的新型近红外荧光纳米探针：Tra-TTR-A
A Novel NIR Fluorescent Nanoprobe Targeting HER2-Positive Breast Cancer: Tra-TTR-A.
作者信息
Chen Meijuan, Lin Zhousheng, Yao Guangyu, Hong Xi, Xue Xiaolei, Chen Lujia
机构信息
State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Hepatology Unit and Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
出版信息
Bioinorg Chem Appl. 2021 Dec 30;2021:2495958. doi: 10.1155/2021/2495958. eCollection 2021.
TTRE, a photosensitizer molecule, has excellent biofluorescence imaging performance and effective antitumor properties for breast cancer. However, its application in breast cancer treatment is limited due to poor tumor selectivity and lack of targeting ability. In this study, TTRE and trastuzumab were combined to synthesize Tra-TTR-A, a novel near-infrared fluorescent nanoprobe for HER2 positive breast cancer. The targeting and antitumor abilities of Tra-TTR-A in breast cancer were also investigated. Like TTRE, Tra-TTR-A has a stable structure with remarkable optical properties and in vivo imaging capacity. However, Tra-TTR-A not only inhibits tumor growth by generating reactive oxygen species but also kills tumor cells by trastuzumab. In this study, Tra-TTR-A, a new type of near-infrared fluorescent nanoprobe that targets HER2-positive breast cancer, was successfully synthesized. Tra-TTR-A could be used in in vivo imaging, targeted photodynamic therapy, and diagnosis and treatment for breast cancer.
TTRE是一种光敏剂分子，对乳腺癌具有出色的生物荧光成像性能和有效的抗肿瘤特性。然而，由于其肿瘤选择性差和缺乏靶向能力，其在乳腺癌治疗中的应用受到限制。在本研究中，将TTRE与曲妥珠单抗结合，合成了一种用于HER2阳性乳腺癌的新型近红外荧光纳米探针Tra-TTR-A。还研究了Tra-TTR-A在乳腺癌中的靶向和抗肿瘤能力。与TTRE一样，Tra-TTR-A具有稳定的结构，具有显著的光学性质和体内成像能力。然而，Tra-TTR-A不仅通过产生活性氧来抑制肿瘤生长，还通过曲妥珠单抗杀死肿瘤细胞。在本研究中，成功合成了一种靶向HER2阳性乳腺癌的新型近红外荧光纳米探针Tra-TTR-A。Tra-TTR-A可用于体内成像、靶向光动力治疗以及乳腺癌的诊断和治疗。
Zotero 插件